<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Adverse Drug Reactions]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院4种中药注射剂不良反应分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:32</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘丹<sup>1</sup>,赵丽霞<sup>2</sup>,丁长玲<sup>1</sup>,张树平<sup>3</sup>,丁召兴<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘丹<sup>1</sup>,赵丽霞<sup>2</sup>,丁长玲<sup>1</sup>,张树平<sup>3</sup>,丁召兴<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309025&flag=1]]></guid><cfi:id>92</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方甘草酸苷注射液致严重不良反应1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308026&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:59</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张彩霞,成文娜,刘呈华,丁长玲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张彩霞,成文娜,刘呈华,丁长玲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308026&flag=1]]></guid><cfi:id>91</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[1137例药品不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[马晶<sup>1</sup>,毕颖楠<sup>2</sup>,王东芳<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>马晶<sup>1</sup>,毕颖楠<sup>2</sup>,王东芳<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307021&flag=1]]></guid><cfi:id>90</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[兰索拉唑致干咳1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘洪云<sup>1</sup>,刘涛<sup>2</sup>,赵延福<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘洪云<sup>1</sup>,刘涛<sup>2</sup>,赵延福<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307022&flag=1]]></guid><cfi:id>89</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[23例注射用盐酸川芎嗪不良反应分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘慧<sup>1</sup>,陈筱南<sup>2</sup>,孙东<sup>1</sup>,张璞松<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘慧<sup>1</sup>,陈筱南<sup>2</sup>,孙东<sup>1</sup>,张璞松<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306023&flag=1]]></guid><cfi:id>88</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[头孢哌酮舒巴坦钠致过敏性休克1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[梁海月,刘玉菲,尹爱群]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>梁海月,刘玉菲,尹爱群</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306024&flag=1]]></guid><cfi:id>87</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方甘草酸苷注射液致不良反应7例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304027&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:04</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘呈华,丁长玲,成文娜,高菲,刘丹]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘呈华,丁长玲,成文娜,高菲,刘丹</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304027&flag=1]]></guid><cfi:id>86</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[银杏叶提取物注射液致急性房颤1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303028&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[衣建平,王丽]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>衣建平,王丽</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303028&flag=1]]></guid><cfi:id>85</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用头孢曲松钠致过敏性休克及溶血性贫血1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303029&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张曙光,张欢,李莉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张曙光,张欢,李莉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303029&flag=1]]></guid><cfi:id>84</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[烟台市县级药品不良反应监测机构建设的现状]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[梁海月,刘玉菲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>梁海月,刘玉菲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302022&flag=1]]></guid><cfi:id>83</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[328例疑似预防接种异常反应数据分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[路长飞<sup>1</sup>,谢彦军<sup>1</sup>,林鑫<sup>2</sup>,田月洁<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>路长飞<sup>1</sup>,谢彦军<sup>1</sup>,林鑫<sup>2</sup>,田月洁<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301022&flag=1]]></guid><cfi:id>82</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奇正消痛贴膏致不良反应4例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311029&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:01</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张霞,毕良贞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张霞,毕良贞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311029&flag=1]]></guid><cfi:id>81</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[布洛芬口服制剂致不良反应/事件监测数据分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[路长飞,田月洁,谢彦军,崔小康,许莉莉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>路长飞,田月洁,谢彦军,崔小康,许莉莉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310025&flag=1]]></guid><cfi:id>80</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[146例严重药品不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:51</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘振胜,杜静,刘华强,王红程]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘振胜,杜静,刘华强,王红程</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409020&flag=1]]></guid><cfi:id>79</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[外周T细胞淋巴瘤治疗药——Beleodaq]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:51</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[商艳丽<sup>1</sup>,冯巧巧<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>商艳丽<sup>1</sup>,冯巧巧<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409021&flag=1]]></guid><cfi:id>78</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[碘海醇注射液致过敏性休克1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:30</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张曙光,王序杰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张曙光,王序杰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408021&flag=1]]></guid><cfi:id>77</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用单硝酸异山梨酯致一过性视觉改变1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[夏晓君]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>夏晓君</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407020&flag=1]]></guid><cfi:id>76</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[218例儿童药品不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[董传婷,赵孝林,郝丽娜]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>董传婷,赵孝林,郝丽娜</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406021&flag=1]]></guid><cfi:id>75</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[左氧氟沙星联用糖皮质激素致谵妄2例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[尹振中]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>尹振中</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406022&flag=1]]></guid><cfi:id>74</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[造影剂肾病的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:20</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[董艳]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>董艳</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404022&flag=1]]></guid><cfi:id>73</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[克拉霉素缓释片致腹痛1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:20</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[丁海燕,王娇,胡莎莎]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>丁海燕,王娇,胡莎莎</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404023&flag=1]]></guid><cfi:id>72</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用炎琥宁在儿童应用的安全性分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:23</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[王学玲,燕友美]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王学玲,燕友美</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401021&flag=1]]></guid><cfi:id>71</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[安全使用化妆品调查分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张军华<sup>1</sup>,赵玉娥<sup>1</sup>,周艳丽<sup>2</sup>,高菲<sup>2</sup>,李燕<sup>2</sup>,丁长玲<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张军华<sup>1</sup>,赵玉娥<sup>1</sup>,周艳丽<sup>2</sup>,高菲<sup>2</sup>,李燕<sup>2</sup>,丁长玲<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411021&flag=1]]></guid><cfi:id>70</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[151例儿童严重药品不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:35</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[孙金刚<sup>1</sup>,郑祝华<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙金刚<sup>1</sup>,郑祝华<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411022&flag=1]]></guid><cfi:id>69</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿昔洛韦致急性肾功能不全1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[王秀丽,李萍,梁启武]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王秀丽,李萍,梁启武</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410021&flag=1]]></guid><cfi:id>68</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方右旋糖酐40注射液致过敏性休克1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[胡国仕,徐文云,余德松]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡国仕,徐文云,余德松</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410022&flag=1]]></guid><cfi:id>67</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用灯盏花素不良反应影响因素logistic回归分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[李玲<sup>1</sup>,葛泉丽<sup>2</sup>,郭绍梅<sup>3</sup>,姜善玲<sup>4</sup>,李莲花<sup>5</sup>,陶萍<sup>6</sup>,崔明超<sup>7</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李玲<sup>1</sup>,葛泉丽<sup>2</sup>,郭绍梅<sup>3</sup>,姜善玲<sup>4</sup>,李莲花<sup>5</sup>,陶萍<sup>6</sup>,崔明超<sup>7</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508022&flag=1]]></guid><cfi:id>66</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[山东省化妆品不良反应监测相关情况问卷调查(医疗机构篇)]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[路长飞<sup>1</sup>,翟淑越<sup>2</sup>,王东芳<sup>3</sup>,王晓骏<sup>1</sup>,王冰洁<sup>2</sup>,范伟<sup>4</sup>,邱健珉<sup>5</sup>,张翠芳<sup>6</sup>,田月洁<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>路长飞<sup>1</sup>,翟淑越<sup>2</sup>,王东芳<sup>3</sup>,王晓骏<sup>1</sup>,王冰洁<sup>2</sup>,范伟<sup>4</sup>,邱健珉<sup>5</sup>,张翠芳<sup>6</sup>,田月洁<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507022&flag=1]]></guid><cfi:id>65</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院245例药品不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张琳<sup>1</sup>,辛贵林<sup>2</sup>,高靖<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张琳<sup>1</sup>,辛贵林<sup>2</sup>,高靖<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504020&flag=1]]></guid><cfi:id>64</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[硫酸依替米星用于治疗肺部感染的不良反应分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[宁微微,苏乐群]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宁微微,苏乐群</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503018&flag=1]]></guid><cfi:id>63</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院328例门诊患者药物不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘东华,王晓君,于馨,王堃,郭欣,韩志武]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘东华,王晓君,于馨,王堃,郭欣,韩志武</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502019&flag=1]]></guid><cfi:id>62</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[苦参素葡萄糖注射液致过敏性休克1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[李雪静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李雪静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502020&flag=1]]></guid><cfi:id>61</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[180例药物性肝损害回顾性调查研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘伟红]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘伟红</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501021&flag=1]]></guid><cfi:id>60</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[替罗非班致急性血小板减少1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张弘宇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张弘宇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501022&flag=1]]></guid><cfi:id>59</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[参芎葡萄糖注射液致高血压危象1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<正>1病例患者,女,79岁,患者因“腰背部疼痛,活动受限1月余”于2014年7月30日入院。查体:体温(T):37.1 ℃,脉搏(P):72次/分,呼吸(R):18次/分,血压(BP):140/80 mmHg。辅助检查:MRI示:腰椎退行性变,L4椎体向前Ⅰ度滑脱,L1/2,L5/S1椎间盘膨出变性,T12压缩性骨折,L4压缩...]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[张夏兰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张夏兰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512018&flag=1]]></guid><cfi:id>58</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[甲硝唑葡萄糖注射液致高热1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/4/25 9:06:02</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[肖玉芹,孙国军]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>肖玉芹,孙国军</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511021&flag=1]]></guid><cfi:id>57</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用头孢曲松钠致死亡1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[崔冉,翟淑越,刘宏明]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>崔冉,翟淑越,刘宏明</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510018&flag=1]]></guid><cfi:id>56</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Reason analysis and countermeasure exploration of adverse reactions of Chinese medicine injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chinese medicine injection is a novel preparation of Traditional Chinese medicine.It is characterized by safety, high bioavailability,and fast onset of action when compared with regular traditional Chinese medicine decoction.However,its adverse reactions (ADR) is grown.Drug quality,drug processing,adjuvant,technology,quality specification and clinical application,except of individual difference of patients and effective component,were analyzed in this paper,and rational suggestions were proposed to minimized or avoid the risk of ADR.]]></description>
<pubDate>2016/10/27 9:55:13</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LIU Hongming<sup>1,2</sup>, ZHANG Ye<sup>3</sup> and SONG Bin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Hongming<sup>1,2</sup>, ZHANG Ye<sup>3</sup> and SONG Bin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607019&flag=1]]></guid><cfi:id>55</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and considerations on the data standardization of adverse drug reaction in Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the status of the standardization of drug adverse reaction data in Shandong Province,and to considerate the methods and measures to improve the standardization of the data.<b>Methods</b>  The key parameters of adverse drug reaction data reported by 2012～2014 in the province were analyzed,and the problems existed in the standardization of data were analyzed.<b>Results</b>  The standardization degree of adverse drug reaction data of Shandong province has increased year by year,but there were problems such as input errors,incomplete data,incomplete database and so on.The non-standardized rates of drug approval number,approved drug name,pharmaceutical producing enterprises,adverse reactions were 4.46%,0.56%,1.24%,1.63%,respectively.<b>Conclusion</b>  To improve the standardization of drug adverse reaction monitoring data,we should strengthen the technical training,establish the system of report and audit,develop the information assistant system.]]></description>
<pubDate>2016/6/21 15:47:30</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[YIN Yangao<sup>1</sup>, WANG Xiaojun<sup>2</sup>, WANG Ling<sup>3</sup> and TIAN Yuejie<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YIN Yangao<sup>1</sup>, WANG Xiaojun<sup>2</sup>, WANG Ling<sup>3</sup> and TIAN Yuejie<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606020&flag=1]]></guid><cfi:id>54</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A questionnaire survey of cosmetics adverse reactions monitoring in Shandong Province（cosmetics production enterprises＆cosmetics management enterprises）]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To understand the current situation of cosmetic adverse reaction monitoring in cosmetics production enterprises and enterprises in Shandong Province, and to put forward proposals for the  cosmetic adverse reaction monitoring.<b>Methods</b>  Designing questionnaires and sending to a part of the cosmetics production enterprises and management enterprises in Shandong province to carry out the questionnaire survey.<b>Results</b>  The cosmetics which are produced or sold by enterprises have a large number of varieties. The size of enterprises is small and scattered. There're some problems about the awareness of cosmetic adverse reaction and the development of monitoring work:More than 20% of the enterprises don't know <i>Diagnostic Criteria and Principles of Management of Skin Diseases Induced by Cosmetics</i> or that the general adverse reaction of cosmetics should be reported to the monitoring department;Most staff who are engaging in adverse reaction monitoring are part-time,or there is on one to do this work. 21.84% production enterprises and 17.22% management enterprises don't want to collect the data or take measures to inform the public.<b>Conclusion</b>  The cosmetics production enterprises and management enterprises' awareness of cosmetic adverse reaction monitoring's importance should be improved by training, and enterprises should be encouraged and promoted to carry out the monitoring work.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LU Changfei<sup>1</sup>, LIU Yufei<sup>2</sup>, WANG Dongfang<sup>3</sup>, WANG Xiaojun<sup>1</sup>, YIN Aiqun<sup>2</sup>, CHANG Hong<sup>4</sup>, XIE Hua<sup>5</sup>, ZHANG Junhua<sup>6</sup> and TIAN Yuejie<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Changfei<sup>1</sup>, LIU Yufei<sup>2</sup>, WANG Dongfang<sup>3</sup>, WANG Xiaojun<sup>1</sup>, YIN Aiqun<sup>2</sup>, CHANG Hong<sup>4</sup>, XIE Hua<sup>5</sup>, ZHANG Junhua<sup>6</sup> and TIAN Yuejie<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602020&flag=1]]></guid><cfi:id>53</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Adverse reactions and rational use of acetaminophen containing drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the adverse reactions and clinical applications induced by acetaminophen drugs to improve the rationality of clinical drug use.<b>Methods</b>  27 cases of adverse drug reactions induced by acetaminophen in our hospital during the past 5 years, the clinical data were retrospectively analyzed to investigate the types of adverse reaction and influence factors and clinical irrational application by summarizing the content of acetaminophen drugs and their content.<b>Results</b>  69 kinds of drug containing acetaminophen,the main adverse reactions involved in the digestive system,respiratory system,urinary system,blood system,allergic reaction,etc.Clinical application of cold medicine containing acetaminophen was more common.Serious adverse reactions accounted for a higher proportion in 27 cases of adverse reactions collected from our hospital,accounting for 88.89%;There were more cases of respiratory tract infection,16 cases,accounting for 59.26%.<b>Conclusion</b>  With a wide range of acetaminophen drugs,clinical irrational use of the phenomenon should be caused by a high degree of attention,increasing publicity and training efforts to minimize the occurrence of drug damage.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[DING Shaoxing, CHENG Wenna, GAO Fei, XU Yangyang and DING Changling]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Shaoxing, CHENG Wenna, GAO Fei, XU Yangyang and DING Changling</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612016&flag=1]]></guid><cfi:id>52</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of adverse reaction of Levofloxacin Hydrochloride and Sodium Chloride Injection for antimicrobial treatment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the characteristics and rules of adverse reaction of levofloxacin hydrochloride and sodium chloride injection for antimicrobial treatment,ensure the safety of the patients.<b>Methods</b>  To analyze the forty-six cases of adverse reactions  of levofloxacin hydrochloride and sodium chloride injection made by several manufacturers for antimicrobial treatment in a provincial hospital during June 2013 to June 2015.<b>Results</b>  In total Forty-six cases of adverse reactions，the male proportion is higher than female,the highest incidence occurs up to 60 years or older patients;Adverse reactions often happen at high dose of patients;Main clinical involving organ or system are the skin and its accessories damage、digestive system damage、injection site damage；The common time happens for the first 30 minutes；Sometimes would occur severe allergic reactions.<b>Conclusion</b>  Drugs should be provided reasonable according to the instruction,and more attention should be paid to the special group of patients and their reactions,ensure the safety of the patients.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHU Yuyan, XU Wendong and CHENG Chunping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Yuyan, XU Wendong and CHENG Chunping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612017&flag=1]]></guid><cfi:id>51</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[紫杉醇注射液致严重的过敏反应1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/10/12 14:45:16</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[FANG Zhaoyun, HOU Hongling and YU Ruirui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FANG Zhaoyun, HOU Hongling and YU Ruirui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610017&flag=1]]></guid><cfi:id>50</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and response of adverse reaction of Hydroxyethyl Starch 40 Sodium Chloride Injection for rescue]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the characteristics and rules of adverse reaction of Hydroxyethyl Starch 40 Sodium Chloride Injection for rescue,ensure the safety of the patients.<b>Methods</b>  To analyze the 53 cases of adverse reactions of Hydroxyethyl Starch 40 Sodium Chloride Injection made by several manufacturers for antimicrobial treatment in a provincial hospital during January 2016 to December 2016.<b>Results</b>  In total 53 cases of adverse reactions,the female proportion was higher than male,the highest incidence occured up to 60 years or older patients;Adverse reactions often happened at high dose of patients;Main clinical involving organ or system were the systemic reactions and skin and its accessories damage;The common time happened for the first 30 minutes;Sometimes would occure severe allergic reactions.<b>Conclusion</b>  Drugs should be provided reasonable according to the instruction,and more attention should be paid to the special group of patients and their reactions,congtrol the dripping speed to ensure the safety of the patients.]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHU Yuyan and QI Gaoqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Yuyan and QI Gaoqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708016&flag=1]]></guid><cfi:id>49</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用头孢哌酮钠舒巴坦钠致过敏性休克死亡1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[KONG Xianghong, MA Yongfang and YAN Tingting]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KONG Xianghong, MA Yongfang and YAN Tingting</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708017&flag=1]]></guid><cfi:id>48</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of 278 cases of adverse drug reaction of Mezlocillin Sodium and Sulbactam Sodium for Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the general regularity and characteristics of adverse reactions (ADR) of Mezlocillin Sodium and Sulbactam Sodium for Injection,and guide the clinical rational use of drugs.<b>Methods</b>  30 articles on ADR of Mezlocillin Sodium and Sulbactam Sodium for Injection collected from "CNKI" and "Wanfang Database" and 2011~2017 242 cases in 6 years in our hospital were carried out with statistics and analysis.<b>Results</b>  The ADRs of Mezlocillin Sodium and Sulbactam Sodium for Injection had nothing to do with gender differences,but there were related with individual differences of patients,clinical use and combined medication.The main types of ADR had skin and appendages damage and gastrointestinal reactions,accounted of 80%,the severe ADRs were allergic shock,liver damage,etc.,which occured in the early stages of medication,clinical application should be strengthened monitoring.<b>Conclusion</b>  Many drugs had incompatibility combined with Mezlocillin Sodium and Sulbactam Sodium for Injection,and the clinical manifestation of ADRs was complex and diverse.Therefore,we should strengthen the monitoring of drug safety,strictly improve the level of rational drug use,to ensure the safety and effective use of drugs.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LI Fengrong, LIANG Hongying, YIN Defen and ZHU Tingjun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Fengrong, LIANG Hongying, YIN Defen and ZHU Tingjun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707017&flag=1]]></guid><cfi:id>47</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress on cause of adverse reaction of traditional Chinese medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide the references information in clinical application by discussing the incidence general pattern and feature of traditional Chinese medicine (TCM) injections adverse reactions.<b>Methods</b>  The present situation,types,causes and countermeasures of adverse reactions were systematically reviewed by retrospective study.<b>Results</b>  Adverse reactions were allergic reactions,respiratory system,cardiovascular system and digestive system,such as organ damage.The main adverse reactions were related to medicinal ingredients and quality, manufacturing process,quality standards, materials,solvents,individual differences, etc.<b>Conclusion</b>  Improving quality standards,standardized package insert and listed after the evaluation work to reduce the incidence of adverse reactions.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[HAO Cui<sup>1</sup> and LIU Fengqin<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAO Cui<sup>1</sup> and LIU Fengqin<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706017&flag=1]]></guid><cfi:id>46</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of 13 cases of Bozhi Glycopeptide Injection ADR]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To discuss the rational use of Bozhi Glycopeptide Injection.<b>Methods</b>  Retrospective study was used to analyze 13 cases of Bozhi Glycopeptide Injection ADR reported statistically in 2016 and drug instruction,in accordance with children's age,gender,weight,the type of report,as well as ADR performance,the drug frequency of ADR occurred,the time after drug use of ADR,the duration of ADR etc.<b>Results</b>  In the 13 cases of ADR reports,the children's average age was (1.99±1.34) years,the average weight was (12.12±4.98)kg,the average drug frequency of ADR occurred was (4.92±4.35)times,the average time after drug use of ADR occurred was (0.55±0.22)h,the duration of ADR was (23.43±30.75)h.<b>Conclusion</b>  Bozhi Glycopeptide Injection information was inadequate,it was recommended that manufacturers should improve the drug instruction.Owing to non-standard use in clinical,we suggested decreasing off-label drug use,enhancing the observation after medication,doing a good first aid treatment.Once serious ADR appear,the agents causing the effects must be stopped and suitable remedies should be introduced immediately,trying best to minimize the seriousness.]]></description>
<pubDate>2017/5/23 16:01:10</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHAO Xiaolin, HAO Lina and ZHANG Yichi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Xiaolin, HAO Lina and ZHANG Yichi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705017&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[重组人白细胞介素-11致不良反应3例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[YU Hao, LIU Weihong and LI Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Hao, LIU Weihong and LI Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703018&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Investigation on cognition of adverse reaction for cosmetics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>   To investigate and analyze the regulities and features of cosmetics adverse reaction in order to guide costumers to selecet  it correctly and use it safely,provide proof and suport for monitoring branchesstatus and reduce  cosmetics adverse reaction.<b>Methods</b>  185 cases of cometics adverse reaction were collected and analyzed by sex,age,prfession,catergory,and impactor factors.<b>Results</b>   In this series,it was found that  there were 184 females(accounting for 99.46%)cand 1 male(accounting for 0.54%), aged mainly from 20 to 40,17cases of severe adverse reactions(accounting for 9.19%) ,168 cases of  general  adverse reaction(accounting for 90.81%),68 cases of allergy reactions(accounting for 36.76%) ,416 categories of cosmetics,151 brands,175 cases of facial  lesions(accounting for 81.78%),15 cases of neck lesions(accounting for 7.01%),shapes of skin lesions with a occuring sequence  of  erythema,papule,edema and so on,138 case of contact dermatitis(accounting for 73.40%),22 cases of hormone-dependent dermatitis(accounting for 11.70%),20 cases of cometics acneiforms(accounting for 10.64%),31 cases of positive manifestations(accounting for 37.35%)and 52 cesess of negtive manifestations(accounting for 62.65%) among 83 cases of  valid cosmetics patch test.Positive ratio  with 29.79% of patch test of cosmetics bought from beauty institutions and  positive ratio  with 26.53% of patch test of cosmetics  from online shopping.<b>Conclusion</b>  The major kind of cosmetics adverse reactions is contact ermatitis,monitoring on cosmetics from online shopping and beauty shop should be strengthened and cosmetics patch test should be extensively performed that would be beneficial to costumers in selecting and using cosmetics.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[DING Changling<sup>1</sup>, DING Zhaoxing<sup>1</sup>, GAO Yu<sup>1</sup>, LI Haiying<sup>1</sup>, LI Na<sup>1</sup> and LI Yuji<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Changling<sup>1</sup>, DING Zhaoxing<sup>1</sup>, GAO Yu<sup>1</sup>, LI Haiying<sup>1</sup>, LI Na<sup>1</sup> and LI Yuji<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701017&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of 17 cases of adverse drug reactions caused by intravenous Vitamin K1 Injection in children]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the influencing factors and regularity of adverse drug reactions of Vitamin K<sub>1</sub> Injection,and provide the basis for children's safety and rational use of drugs.<b>Methods</b>  17 cases of adverse drug reactions induced by Vitamin K<sub>1</sub> Injection in our hospital from 2012 to 2017 were analyzed. <b>Results</b>  Adverse drug reaction of Vitamin K1 Injection is related to the quality of the drug itself, the physiological characteristics and the clinical use of the drug.<b>Conclusion</b>  Should strengthen the rational use and management of Vitamin K<sub>1</sub> Injection, to ensure the safety of children's medication.]]></description>
<pubDate>2018/9/29 14:08:06</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[WANG Xiaoyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xiaoyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809017&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on 94 cases of adverse drug reactions of Zoledronic Acid Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To put forward the effective measures for preventing the occurrence of adverse reactions and ensure the safety of the patients by collecting the common adverse reactions of Zoledronic Acid Injection in clinic,and analyzing the characteristics and laws of adverse reactions.<b>Methods</b>  According to the age and sex of the population,the cumulative system-organ,the time of occurrence,the new or the adverse effect of zoledronic acid injection on 94 cases of zoledronic acid injection adverse reactions collected by Zibo Center for ADR Monitoring from January 1st 2016 to September 30th 2016.<b>Results</b>  The incidence of adverse events proportion of female was more higher than male,The incidence of adverse reactions was highest in patients over 46 years of age,involving mainly systemic organ or system damage,including nervous system,digestive system,skin and the appendages,urinary system and respiratory system.Adverse reactions occurred less than 24 hours after treatment within the fast hair type of adverse reactions.<b>Conclusion</b>  Pharmaceutical manufacturers should strengthen the study on the use of drugs in women patients and middle-aged and elderly patients.It should be closely monitored and regulate medication in clinical to ensure the medication safety of patients.]]></description>
<pubDate>2018/8/27 10:55:11</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Xin and ZHOU Wenqi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xin and ZHOU Wenqi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808016&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丙戊酸钠致表皮坏死松解症1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2018/8/27 10:55:11</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[QU Hui<sup>1</sup>, WANG Dengxu<sup>1</sup> and LU Jing<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QU Hui<sup>1</sup>, WANG Dengxu<sup>1</sup> and LU Jing<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808017&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of adverse drug reactions in 2 527 children]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the regularity and the characteristics of pediatric adverse drug reactions (ADR) in our city in order to promote rational drug use of children. <b>Methods</b>  In retrospective study, 2 527 pediatric ADR cases collected from our city during January 2015~June 2017 were analyzed statistically. <b>Results</b>  Among 2 527 pediatric ADR cases, 1 544 cases were male(61.10%), 983 cases were female(38.90%).The incidence of ADR in patient age under one year old was the highest(28.61%);Anti-infective medicine was the largest part of drugs which leaded to ADR.(23.13%). Most of the cases were induced by intravenous injection(68.81%).Injection caused the biggest portion of ADR(67.1%); The lesion of skin and its appendages were the most common clinical manifestation of ADR(48.39%) in 2527 pediatric ADR cases; Doctors reported the most ADR case(51%). <b>Conclusion</b>  We should pay attention to the ADR of anti-infective medicine for children by mastering clear indication, promoting rational drug use, in order to prevent or reduce ADR.]]></description>
<pubDate>2018/6/13 9:41:49</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHAOU Guangyu<sup>1</sup>, CAO Fen<sup>2</sup> and SU Hua<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAOU Guangyu<sup>1</sup>, CAO Fen<sup>2</sup> and SU Hua<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805016&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of 9 cases of deaths coused by derivatives of Recombinant HumanTissue-type Plasminogen Activator for Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the general characteristics of fatal adverse drug reactions (ADR) induced by derivatives of Recombinant HumanTissue-type Plasminogen Activator(rPA) for Injection in order to provide references and influence factor for rational and safe clinical drug use.<b>Methods</b>  Fatal ADR cases induced by rPA in Shandong province database of adverse drug reactions during 2012～2018 were collected and analyzed statistically.<b>Results</b>  The main performance of the fatal ADR of rPA were allergic reaction and bleeding, which were related to the age of patients, original disease,previous history and combined medication.<b>Conclusion</b>  Fatal ADR of rPA should be strengthened in clinical.Medical staff should weigh the advantages and disadvantages before the use of rPA and grasp the indications and taboos of thrombolytic therapy accurately.]]></description>
<pubDate>2018/10/18 9:58:39</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[CUI Xiaokang, LU Changfei, XU Lili, LIU Wenwen and WU Shifu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Xiaokang, LU Changfei, XU Lili, LIU Wenwen and WU Shifu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810017&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院133例中药注射剂不良反应报告分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:17</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘梅霞,赵小燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘梅霞,赵小燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909013&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Survey of Bai public’s cognition of adverse drug reaction in Yunnan Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate and understand the awareness of the bai public’s cognition of adverse drug reaction (ADR) in Yunnan Province,then to provide basis and Suggestions for ensuring safe and effective clinical medication, facilitating ADR monitoring and further improving ADR monitoring.<b>Methods</b>  The questionnaire for the recognition of adverse drug reactions was designed, and the questionnaire was filled out for the general public of bai pubic in yunnan province and local medical professionals, and the valid questionnaires were collected for statistical analysis.<b>Results</b>  A total of 204 questionnaires were issued, 204were recovered,with a recovery rate of 100.00%.The investigated population is not paying enough attention to adverse drug reactions and is not aware of safe drug use.The definition of ADR is unclear, the knowledge of ADR reporting is not understood, and the awareness of reporting is not enough.<b>Conclusion</b>  The general awareness of medicine among the bai people in yunnan province is limited, and some remote areas have a severe lack of knowledge about ADR. Therefore, the publicity of ADR awareness should be improved, and the public awareness of ADR should be enhanced.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Wenping, YANG Yumin, ZONG Sifan, MA Dalong and MA Yage]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenping, YANG Yumin, ZONG Sifan, MA Dalong and MA Yage</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905015&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical analysis of 154 inpatients with drug eruption]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the causative drugs, clinical types and the relationship between them.<b>Methods</b>  Clinical data were collected from 154 inpatients with drug eruption in Binzhou medical college affiliated hospital, January 2011 to June 2018,and analyzed retrospectively.<b>Results</b> The percentage of inpatients with drug eruption among all inpatients in the Department of Dermatology is 7.1%. Infectious diseases（84 cases, 54.5%） are the most of primary diseases. 115 (74.7%) were caused by single drugs, and 39 (25.3%) by multiple drugs. Among the 115 cases of drug eruption caused by single drugs, the top three causative drugs were Beta-lactam antibiotics（33 cases）, acetaminophen(20 cases) and carbamazepine (11 cases) in non-severe drug eruption, and severe drug eruption. Traditional Chinese medicine（9 cases）is another causative drug in non-severe drug eruption. Of the 154 patients, 116 presented with non-severe eruption and 38 with severe eruption. A total of 139 (90.3%) patients with drug eruption received glucocorticoid treatment. Totally, 5 patients with drug eruption were treated with combined intravenous immunoglobulin (IVIG) because of poor response to glucocorticoids alone. No cases were followed up to death.<b>Conclusion</b>  β-lactam antibiotics, acetaminophen and carbamazepine are the main causative drugs for severe and non-severe drug eruption,while traditional Chinese medicine is another important causative drug for non-severe drug eruption. Infection is a certain influence factor on the occurrence, development and prognosis of drug eruption.]]></description>
<pubDate>2019/4/12 10:55:30</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[GAO Yu<sup>1</sup>, WANG Zihan<sup>1</sup>, GAO Fei<sup>2</sup>, ZHANG Ye<sup>2</sup>, WU Shifu<sup>3</sup>, TIAN Yuejie<sup>3</sup> and DING Changling<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Yu<sup>1</sup>, WANG Zihan<sup>1</sup>, GAO Fei<sup>2</sup>, ZHANG Ye<sup>2</sup>, WU Shifu<sup>3</sup>, TIAN Yuejie<sup>3</sup> and DING Changling<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903014&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[儿童医院94例新生儿药品不良反应分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[王晓燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王晓燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910012&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[One case of severe neurological adverse reactions and convulsions caused by Indomethacin Suppository]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A 33 year old female patient was prescriped 2/3 of Indomethacin Suppository once dose for dysmenorrhea.Patient had adverse reactions such as  dizziness, wheezing discomfort, numbness of hands and feet, convulsions, opisthotonus, neck stiffness, severe electrolyte imbalance,respiratory alkalosis etc just half hour after insert the medication. Arterial blood gas analysis: pH 7.459, PCO2 21.1 mmHg, PO2 144.2 mmHg, K+ 2.94 mmol·L-1. The reaction relief after 10mg diazepam IM once dose, yet reoccurred four hours later. After another 5mg diazepam IM once dose and phenobarbital 100 mg IV dose, adverse reactions eased off and patient back to normal. Suggesting indomethacin induced adverse reactions. Patient discharged on the third day with no adverse reactions.And it didn't happen after the following three months.]]></description>
<pubDate>2020/9/30 14:34:47</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHAO Lei, SHENG Dongqin, ZHONG Lihong, LIU Xianghong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Lei, SHENG Dongqin, ZHONG Lihong, LIU Xianghong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009014&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Literature analysis of 92 cases of adverse reactions induced by Articaine in stomatology medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the regularity and characteristics of adverse drug reactions  induced by articaine in stomatology, and to provide reference for clinical medication.<b>Methods</b>  Literatures on adverse reactions induced by articaine in the department of stomatology were retrieved from CNKI China Academic Journal Network Publishing Database and Digital Journal Full Text Database (Wanfangshan Mirror) from 1998 to 2019, and 92 cases were summarized and analyzed.<b>Results</b>  In 92 cases of adverse reactions, there were more women than men patients, and occured more frequently at the age group of 3~10 years old.The incidence of ADRs was higher 1~10 min and one day after injection.Generally, multiple systems of the body were involved, and the clinical manifestations were complex and diverse. Injection ulcer formation and allergic reaction were the most common.<b>Conclusion</b>  Stomatologists should inquire about the medical history in detail, pay attention to the adverse reactions of articaine and insist on rational drug use.]]></description>
<pubDate>2020/9/30 14:34:47</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LIU Qin, CUI Yanjun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Qin, CUI Yanjun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009015&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[头孢呋辛钠致低钾血症个案报道]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Wenhui, WANG Shaolian, ZHANG Tingcui, MI Nianrong and SUN Pei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenhui, WANG Shaolian, ZHANG Tingcui, MI Nianrong and SUN Pei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004013&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2014~2019年我院头孢曲松迟发型过敏反应的临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:27</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[刘翠玲,马海燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘翠玲,马海燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001014&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[磷酸奥司他韦胶囊致精神异常2例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/11/13 13:56:47</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[SANG Yuan<sup>1</sup>, YUAN Minghui<sup>1</sup>, WANG Qian<sup>1</sup>, GU Xiaoyun<sup>1</sup>, HUO Yanfei<sup>2</sup>, LIN Xinyi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SANG Yuan<sup>1</sup>, YUAN Minghui<sup>1</sup>, WANG Qian<sup>1</sup>, GU Xiaoyun<sup>1</sup>, HUO Yanfei<sup>2</sup>, LIN Xinyi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010017&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[某市基于报告比值比法挖掘药品不良反应风险信号的探索]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/9/9 11:28:13</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[王登旭<sup>1</sup>，马栋栋<sup>2</sup>，曲辉<sup>1,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王登旭<sup>1</sup>，马栋栋<sup>2</sup>，曲辉<sup>1,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108016&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奥美拉唑肠溶胶囊致全身水肿1例]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHI Xiaohui<sup>1</sup>, WANG Xiaogang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHI Xiaohui<sup>1</sup>, WANG Xiaogang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105016&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A case of fluvastatin-induced  elevation and rhabdomyolysis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A 79-year-old female patient with coronary heart disease received fluvastatin, meanwhile she was given aspirin, hydro clopidogrel, bisoprolol fumarate and isosorbide mononitrate. The patient developed weakness and pain in double lower limbs with loss of appetite two months after the first dose. Laboratory tests showed creatine kinase (CK) 50 774 U·L<sup>-1</sup>, alanine aminotransferase (ALT) 706.9 U·L<sup>-1</sup>, aspartate aminotransferase (AST) 1 294 U·L<sup>-1</sup>. Fluvastatin was withdrawn and other drugs continued. Meanwhile tiopronin and silibin meglumine were given for liver protection treatment. Laboratory tests showed CK 38 134 U·L<sup>-1</sup> in the next day. After 5 days of fluvastatin withdrawn, the lower limbs weakness disappeared. Seven days after withdrawn, laboratory tests showed CK 2144 U·L<sup>-1</sup>, ALT 494.6 U·L-1, AST 189 U·L<sup>-1</sup>. Both hepatic transaminase and myocardial enzyme basically returned to normal at one month and three months of follow-up after withdrawn.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[QIU Mengru<sup>1,2</sup>, WU Mingli<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIU Mengru<sup>1,2</sup>, WU Mingli<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102017&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the effect of PDCA cycle in the adverse drug reactions monitoring in our hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the effect of applying the PDCA cycle in hospital adverse drug reaction (ADR) reporting and monitoring,to improve the standardization of ADR reporting and monitoring in our hospital, and to promote the safety of clinical medication.<b>Methods</b>  Analyze the quantity and quality fo ADR reporting and monitoring of our hospital in 2017-2020, Evaluate the effect of applying the PDCA cycle method since 2019.<b>Results</b>  After the PDCA cycle’s application, the quantity of reported ADR, new/serious ADR reports’ quantity and the record rate of the course of the disease increased.<b>Conclusion</b>  The intervention of PDCA cycle has significantly improved the quality of ADR monitoring in our hospital, which will help reduce the risk of clinical medication and ensure the safety of patients' medication.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[CHENG Zhentian, ZHOU Yun, YUAN Xiangxiang, SHAN Lini]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Zhentian, ZHOU Yun, YUAN Xiangxiang, SHAN Lini</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110016&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the feasibility of monitoring adverse drug reactions in outpatients outside the hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the feasibility of the application of information technology in the monitoring of adverse drug reactions (ADR) in outpatients.<b>Methods</b>  An outpatient ADR monitoring platform was established and a monitoring system was formed by using Wechat Offical Account and telephone follow-up to monitor ADR in outpatients which happened outside the hospital.<b>Results</b>  The outpatient ADR monitoring platform ran smoothly. In 2019 ADR monitoring was carried out on outpatients in our hospital. A total of 83 ADR cases were detected, including 39 cases of chemical medicine, 42 cases of Chinese patent medicine, and 2 cases of medical materials. All of ADR were treated in time and no serious adverse consequences were found.<b>Conclusion</b>  Using information technology to monitor ADR in outpatients which happened outside the hospital can improve the awareness of reporting ADR，which helps to effectively reduce the unreported ADR in outpatients, deal with ADR in a timely manner, so as to better guarantee the safety of drug use.]]></description>
<pubDate>2021/11/11 17:05:08</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[BI Siji, TAN Rong, JIAO Huimin, LIN Sen, TIAN Hao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BI Siji, TAN Rong, JIAO Huimin, LIN Sen, TIAN Hao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110017&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on monitoring pathway of drug induced liver injury in medical institutions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the characteristics and high risk factors of drug-induced liver injury, and to explore the establishment of DILI monitoring path in medical institutions. <b>Methods</b>  we statistically analyzed the related influencing factors of 5 066 suspected DILI patients from the database of ADR Monitoring Center between January 1,2013 and July 31,2018 and 181 suspected DILI patients between January 1,2016 to December 31, 2017 in the Second Affiliated Hospital of Shandong First Medical University. <b>Results</b>  Most patients aged 40~59 years; the largest proportion of anti-infective drugs involved; the patient's weight, latency, drug type and primary disease were the influencing factors of severe DILI. <b>Conclusion</b>  According to the characteristics and influencing factors of drug-induced liver injury, the establishment of a monitoring path for drug-induced liver injury in medical institutions is conducive to reducing the risk of drug-induced liver injury.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[XU Lili<sup>1</sup>, TIAN Yuejie<sup>1</sup>, SU Fengyun<sup>2</sup>, XIE Yanjun<sup>1</sup>, LI Xia<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Lili<sup>1</sup>, TIAN Yuejie<sup>1</sup>, SU Fengyun<sup>2</sup>, XIE Yanjun<sup>1</sup>, LI Xia<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208014&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A Case analysis of pulmonary Aspergillus infection patients with abnormal excitatory adverse reactions induced by voriconazole]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the causes of adverse reactions and adjust the administration plan in time by analyzing a patient with abnormal excitatory reaction induced by voriconazole.<b>Methods</b>  Clinical pharmacists use blood concentration monitoring of therapeutic drugs as a technical means, medical guidelines and literature as information support, based on the actual disease status of patients, to provide reference for clinicians and improve the treatment plan.<b>Results</b>  The doctor adopted the clinical pharmacist's suggestion to change the treatment plan, the adverse reaction symptoms were relieved and the compliance of patients was improved. <b>Conclusion</b>  In the face of complex and changeable conditions, it is not only necessary to use drugs according to the instructions, but also need to develop individualized medication plan according to the physiological and pathological conditions of patients.]]></description>
<pubDate>2022/9/5 13:24:46</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[WANG Yi, ZHI Junna, TAN Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Yi, ZHI Junna, TAN Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208015&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A case of gross hematuria induced by Piperacillin-tazobactam Sodium]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A 46-year-old male patient was admitted to the hospital for rehabilitation treatment due to "poor left limb movement for more than 6 months". Fever, white blood cells, percentage of neutrophils, and c-reactive protein levels were increased after admission. Piperacillin-tazobactam sodium (4.5g, q8h, ivdrip) was given to him for infection. Gross hematuria appeared at the night. On the 2nd day after treatment, and the routine urine: erythrocyte 8493/μL. On the 3rd day after the treatment, the gross hematuria was increased, and the routine urine: erythrocyte 16469/μL. The adverse reaction of Piperacillin-tazobactam sodium was considered. Piperacillin-tazobactam sodium was immediately discontinued and changed to Levofloxacin and Sodium Chloride Injection (2.0 g, q 12 h, ivdrip). After 2 days, the routine urine: erythrocyte 8675/μL. After 5 days, routine urine:erythrocyte 64/μL. The patient had no gross hematuria untill 2020.09.21.]]></description>
<pubDate>2022/6/8 14:30:17</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Lina<sup>1</sup>, ZHOU Guangjie<sup>1</sup>, WANG Bing<sup>1</sup>, YUAN Minghui<sup>2</sup>, GAO Na<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lina<sup>1</sup>, ZHOU Guangjie<sup>1</sup>, WANG Bing<sup>1</sup>, YUAN Minghui<sup>2</sup>, GAO Na<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205017&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A case of rhabdomyolysis caused by Vecuronium Bromide]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Elevated creatine kinase was observed in a 61-year-old male 2 days after surgical administration of "vecuronium, sufentanil, etomidate, dexmedetomidine, sevoflurane, and propofol".After 7 days, the patient was transferred to ICU and given "vecuronium bromide 20 mg+0.9% sodium chloride injection 50 mL micropump". The patient's urine volume was reduced and turned brown, and the maximum creatine kinase was 96 times of the upper limit of > reference value by laboratory examination, and the myoglobin was 18358 ng·L<sup>-1</sup>, which was diagnosed as rhabdomyolysis.Seven days after the withdrawal of vecuronium bromide and the administration of fluid rehydration, alkalized urine and diuretic treatment, laboratory tests showed creatine kinase 7212.4 U·L<sup>-1</sup>， and myoglobin > 3000 ng·L<sup>-1</sup>.After 15 days, the patient had increased urine volume and normal urine color. Laboratory tests showed creatine kinase 95 U·L<sup>-1</sup> and myoglobin 506 ng·L<sup>-1</sup>.No decrease in urine volume or color change was observed until the patient was discharged from hospital, and no abnormalities were observed in laboratory tests such as creatine kinase.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[WANG Bing<sup>1</sup>, HUANG Huixuan<sup>1</sup>, LI Jinfeng<sup>1</sup>, ZHOU Guangjie<sup>1</sup>, CHEN Weina<sup>1</sup>, ZHANG Ailun<sup>2</sup>, ZHANG Yuan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Bing<sup>1</sup>, HUANG Huixuan<sup>1</sup>, LI Jinfeng<sup>1</sup>, ZHOU Guangjie<sup>1</sup>, CHEN Weina<sup>1</sup>, ZHANG Ailun<sup>2</sup>, ZHANG Yuan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203016&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Retrospective analysis of 1120 adverse drug reactions/events]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To investigate the occurrence of adverse drug reactions/events in a hospital and analyze their characteristics and outcomes, so as to provide reference for clinical safe and rational drug use. <b>Methods</b>  A retrospective analysis was performed on 1120 ADR/ADE reports uploaded to National Center for ADR Monitoring from 2018 to 2019 in our hospital，to explore the correlation between ADR/ADE and age, gender, weight, drug type, and route of administration. <b>Results</b>  Among the 1120 ADR/ADE reports, the number of new and serious reports was 989 (88.30%),known type of ADR/ADE damage is more serious. The proportion of severe ADR/ADE is not significantly related to gender and weight (<i>P</i>>0.05), but is significantly related to age (<i>P</i><0.05), patients with severe ADR/ADE are older; The main routes of administration are oral (624, 55.71%) and intravenous drip (374, 33.39%). The proportion of severe ADR/ADE caused by oral administration is relatively high; The most reported type of drug is anti-infective drugs (298, 26.61%), and the drug with the highest ratio of severe ADR/ADE is endocrine system drugs (143 cases in total, 132 severe cases, 92.31%); The top three reported organs/systems involved are metabolic and nutritional disorders (249, 22.23%), liver and biliary disorders (178, 15.89%), and vascular, bleeding and clotting disorders (170, 15.18%).The outcome of 999 cases was cured or improved, and 63 cases did not improve. There was no difference in the improvement rate of ADR/ADE with different treatment methods (<i>P</i>>0.05), which was significantly different from that of untreated patients (<i>P</i><0.05); The median incubation period is 7 days, and the recovery period is 1 day.<b>Conclusion</b>  The monitoring of medications for the elderly should be strengthened, and more attention should be paid to the safety of oral medications. Medical staff should be familiar with the known ADR/ADE in order to detect them early and deal with them in time to avoid serious adverse reactions/events.]]></description>
<pubDate>2022/3/16 16:00:23</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LIN Mao<sup>1</sup>, LIU Minhui<sup>1</sup>, CHEN Chongze<sup>1</sup>, DAI Hengfen<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Mao<sup>1</sup>, LIU Minhui<sup>1</sup>, CHEN Chongze<sup>1</sup>, DAI Hengfen<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202015&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on adverse reactions induced by platinum anti-tumor drugs in Chaoshan area]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the adverse reactions induced by the platinum anti-tumor drugs in cancer hospital of Chaoshan area and provide reference on the rational clinical use and management.<b>Methods</b>  A retrospective analysis on the platinum drug adverse reaction cases and distribution, symptom and disease was implemented during from 2009 to 2020 of the Cancer Hospital of Shantou University Medical College, including Cis-platinum, Carboplatin, Nedaplatin and Oxaliplatin. <b>Results</b>  A total of 399 suspected cases on the platinum drugs were reported, taking a proportion of 40.96%. while with 65 cases of severe adverse reaction in all events. Patients with the age from 50-70 years old took the most cases as 270, with a proportion of 67.67%. The most common symptoms were allergies, rashes and bone marrow suppression in all adverse reactions, 182 cases with a proportion of 45.61%. Oxaliplatin caused the most cases as 159, with a proportion of 39.85%. A total of 59 cases were reported as the new adverse reactions but 23 of them were recorded in the drug instruction. Colorectal cancer were the mainly common diseases of the patients with the adverse reactions. <b>Conclusions</b>  Adverse reaction cases induced by the platinum drugs accounted for the highest proportion, especially for the Oxaliplatin, and the related symptoms mainly reflected in immune system. Closely monitoring, seasonable communication between doctors and pharmacists and preventive measures should be used to reduce adverse reactions.]]></description>
<pubDate>2022/2/23 16:42:52</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Yuling<sup>1</sup>, HUANG Xiaoting<sup>2</sup>, CHEN Chen<sup>2</sup>, FANG Ling<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yuling<sup>1</sup>, HUANG Xiaoting<sup>2</sup>, CHEN Chen<sup>2</sup>, FANG Ling<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201013&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of aspirin related gout and hyperuricaemia adverse events based on FDA adverse event database]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The adverse events（AE） signals of aspirin related gout and hyperuricaemia were mined and analyzed by using the FDA adverse event reporting system (FAERS) database, so as to provide reference for clinical safe and rational drug use. <b>Methods</b>  The reported odds ratio (ROR) method was used to mine the AE of gout and hyperuricaemia of aspirin reported in the open FDA OpenVigil 2.1 database from January 1, 2004 to September 30, 2021. <b>Results</b>  The number of AE reported for aspirin associated gout was 625, with a 95% CI of ROR:3.254 (2.997-3.533) and hyperuricaemia was 90, with a 95%CI of ROR: 2.464 (1.989-3.053). The signal intensity of female is higher than that of male, and that of 18-44 age group is higher than that of other age groups. Aspirin used in AE was low-dose.<b>Conclusion</b>  Low dose aspirin is the risk signal of gout and hyperuricaemia. The signal intensity of gout is higher than that of hyperuricaemia. There is no correlation between them as independent AE . The female and 18-44 years old group taking low dose aspirin should take low purine diet, and pay attention to monitoring blood uric acid and gout attack.]]></description>
<pubDate>2023/1/17 13:58:00</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[SUN Haiyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Haiyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212014&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Heart rate slowing induced by Qili Qiangxin Capsules caused by slow heart rate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A case of 86 years old male patients with degenerative heart valvular disease in hospital treatment, due to cardiac function class IV, given Qiliqiangxin Capsules 1.2 g, oral, 3 times/day, improve cardiac function. After 4 days of taking the medicine (10 times, a total of 40 pills), the patient's heart rate fluctuated with the lowest rate of 41 beats/mintimes/min. Maximum 57 times/point. The patient continued to take two doses (48 pills in total), and the heart rate maintained at about 40 beats/min for 12 hours. The heart rate decreased significantly, and the patient felt fatigue weak, mild dizziness and poor appetite. Immediately discontinue Qili Qiangxin Capsules and administer Xinbao Pills 120 mg, po, tid; Levosimendan Injection 12.5 mg+5% Glucose Injection 250 mL, micro pump st Symptomatic treatment. At the same time, digoxin blood concentration showed digoxin > 5.00 ng•mL-1 (normal value range: 0～2.0). After 15 hours, the patient's heart rate was around 70 beats per minute. It returned to normal.]]></description>
<pubDate>2023/8/14 11:14:19</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[YUAN Minghui<sup>1</sup>, GU Xiaoyun<sup>1</sup>, ZHANG Lina<sup>2</sup>, SANG Yuan<sup>1</sup>, WANG Qian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Minghui<sup>1</sup>, GU Xiaoyun<sup>1</sup>, ZHANG Lina<sup>2</sup>, SANG Yuan<sup>1</sup>, WANG Qian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307018&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[One case of Acute urticaria induced by acetaminophen and ibuprofen in an three-year-old child]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the effective treatment to urticaria induced by acetaminophen and ibuprofen and pharmaceutical care.<b>Methods</b>  The clinical case of one three-year-old child of acute urticaria induced by acetaminophen and ibuprofen were reviewed retrospectively. <b>Results</b>  Desloratadine dry suspension and dexamethasone were administered to this child with acute urticaria and a good prognosis was observed.<b>Conclusion</b>  Acute urticaria induced by acetaminophen and ibuprofen was rare but still present in clinical practice. The children should be monitoring as well as anti-allergic treatment when treated with acetaminophen and ibuprofen. Besides, the analysis of drug-related adverse reactions by clinical pharmacist may provide the reference for clinical practice.]]></description>
<pubDate>2023/6/26 13:41:42</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[YE Guihua, LI Huamin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Guihua, LI Huamin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305015&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of 42 Cases of Adverse Reactions Caused by Pentoxifylline Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the characteristics and regularity of adverse drug reaction (ADR) induced by pentoxifylline in our hospital, and to provide suggestions for clinical rational drug use. <b>Methods</b>  Retrospective analysis was used to collect ADRs caused by pentoxifylline reported to the National Adverse Drug Reaction Monitoring System in our hospital from January 17, 2021 to May 31, 2022. The cumulative system-organ and clinical manifestations, clinical outcomes were statistically analyzed. <b>Results</b>  In the 42 ADR reports, 35 cases（83.33%）were known general ADR, 6 cases（14.29%） were new general ADR, and 1 case（2.38%）was new severe ADR. There were 42 patients (including 15 males and 27 females), and the incidence of adverse reactions in patients over 50 years old accounted for 83.33% and most of which occurred within 2 hours of medication (20 patients, 47.62%). The gastrointestinal system damage was the main involved system-organ, a total of 29 cases (46.77%), in clinical manifestations. The recovered time of all patients is mostly within 1-2 days after drug withdrawal or symptomatic treatment. <b>Conclusion</b>  Strengthen the monitoring of pentoxifylline medication to avoid or reduce the occurrence of adverse reactions.]]></description>
<pubDate>2023/2/27 10:11:24</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Xiaojuan, XU Xiaqing, LI Ying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xiaojuan, XU Xiaqing, LI Ying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301014&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A case of drug-induced liver injury caused by Bike Granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A 47-year-old male patient was treated with Bike Granules (10 g, po, tid) due to a gout attack. About 10 days after taking the medicine, he was hospitalized with "yellow skin staining all over the body and yellow sclera". Liver function on admission day: TBiL 40 μmol·L<sup>-1</sup>, UCB 14.2 μmol·L<sup>-1</sup>, ALP 167.1 U·L<sup>-1</sup>, TBA 70.1 μmol·L<sup>-1</sup>, ALT 374.4 U·L<sup>-1</sup>, γ-GT 645.8 U·L<sup>-1</sup>, and AST 291.3 U·L<sup>-1</sup>. Adverse drug reaction considered to be related to BIKE KELI. The patient's liver function returned to normal more than 1 month after discontinuation of the treatment.]]></description>
<pubDate>2023/2/27 10:11:24</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[ZHANG Lina<sup>1</sup>, WANG Bing<sup>1</sup>, YUAN Minghui<sup>2</sup>, LI Jinfeng<sup>1</sup>, ZHOU Guangjie<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Lina<sup>1</sup>, WANG Bing<sup>1</sup>, YUAN Minghui<sup>2</sup>, LI Jinfeng<sup>1</sup>, ZHOU Guangjie<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301015&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical symptoms and treatment of <i>Psoralen</i> induced liver injury based on data mining]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To conduct a retrospective analysis of cases of liver injury caused by taking psoralen and its preparations, to explore the characteristics and laws of liver injury caused by psoralen and its preparations, and to provide a reference for rational clinical use. <b>Methods</b>  Through the in-hospital data search platform, all cases of patients taking Psoralen and Psoralen preparations at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from January 2016 to January 2021 were collected, totaling 37 419 cases, and hospitalized cases diagnosed with liver injury caused by Psoralen and its preparations were screened, and patients with hospitalization time less than two weeks and severely incomplete data were excluded, and SPSS 26.0 was used to statistically analyze the age, gender, purpose of medication, clinical manifestations, and medication regression of the selected cases; Cytoscape v3.9.1 was used to analyze the data mining of the Chinese herbal medicine combinations of the selected cases.<b>Results</b>  A total of 353 cases of liver injury caused by Psoralen and its preparations were collected, including 191 male cases and 162 female cases, with a mean age of 63.12 years and 78.47% of patients over 50 years of age. The purposes of drug use mainly included bone growth promotion (69 cases), anti-inflammatory (63 cases), anti-tumor (83 cases), immune enhancement (53 cases), neuroprotection (2 cases), cardiovascular system (49 cases), and others (31 cases). The drug used was Chinese herbal salt Psoralen in 298 cases, accounting for 84.41%; a total of 55 patients (15.58%) used Psoralen-containing preparations. Patients improved after treatment in 352 cases and were ineffective in 1 case. The top six Chinese herbal preparations with high association with salt Psoralen reinforcing fat were Astragalus membranaceus, Glycyrrhiza glabra, Radix Angelicae Sinensis, Radix et Rhizoma Dioscoreae, Fructus Schisandrae, and Salt Cumin. The top three liver-protecting herbs with high frequency of use were Astragalus, Glycyrrhiza, and Schisandra, and the liver-protecting western drugs were reduced glutathione for injection, lactulose oral solution, and glutathione for injection. <b>Conclusion</b>  Patients should take psoralen during the prescribed dose, clinically should strengthen the monitoring of liver function in middle-aged and elderly patients when taking drugs, pay attention to the quality monitoring of psoralen, and find more effective attenuation methods from the preparation of traditional Chinese medicine.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[WANG Jingyi<sup>1</sup>, LYU Mingyue<sup>2</sup>, YIN Jia<sup>2</sup>, WANG Xin<sup>2</sup>, LIU Hui<sup>1</sup>, FU Chunsheng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jingyi<sup>1</sup>, LYU Mingyue<sup>2</sup>, YIN Jia<sup>2</sup>, WANG Xin<sup>2</sup>, LIU Hui<sup>1</sup>, FU Chunsheng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311017&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on Evaluation Indicators of the International Pharmacovigilance System]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pharmacovigilance is an internationally accepted means of regulating the safety of post-marketing drugs. In order to evaluate the effectiveness of pharmacovigilance systems, indicators for evaluating the capacity of pharmacovigilance systems have been studied and established internationally. In this paper,the research progress of international pharmacovigilance system evaluation indicators and the use of relevant evaluation indicators to carry out pharmacovigilance system evaluation were systematically analyzed, in order to provide ideas for the establishment of pharmacovigilance system evaluation indicator system in China.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LIU Li<sup>1</sup>, LI Li<sup>2</sup>, ZHANG Tao<sup>3</sup>, DING Changling<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Li<sup>1</sup>, LI Li<sup>2</sup>, ZHANG Tao<sup>3</sup>, DING Changling<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311018&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of ADR Reports and Risk Factors of 285 Cases of Arsenious Acid Sodium Chloride Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the characteristics and influencing factors of adverse drug reactions (ADR) of arsenious acid sodium chloride injection, and provide reference for promoting clinical rational drug use.<b>Methods</b>  The ADR reports of 285 cases of arsenious acid sodium chloride injection collected from January 1st, 2005 to December 31st, 2022 were analyzed retrospectively by searching the database of ADR monitoring system in Shandong Province.<b>Results</b>  In 285 cases, the proportion of male patients was higher than that of female patients. People aged 45 ~ 64 account for a relatively high proportion; Adverse reactions mostly occurred within 2 weeks of medication. ADR mainly involves hepatobiliary, gastrointestinal, systemic and other multi-system and organ damages, and the risks of QT interval prolongation, fever and chest tightness are not mentioned in the instructions. <b>Conclusion</b>  Drug marketing license holders should strengthen the research and evaluation of drug safety after marketing, improve the safety content of the instructions; Guide clinical rational medication and strictly follow the instructions for use; Strengthen medication monitoring for elderly patients, especially related indicators of the hepatobiliary system and cardiovascular system, and ensure the safety of drug use by the public.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[HUO Yanfei, LU Changfei, XIE Yanjun, XU Lili, CHANG Hong, SUN Chunxiao, LI Xia]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUO Yanfei, LU Changfei, XIE Yanjun, XU Lili, CHANG Hong, SUN Chunxiao, LI Xia</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407018&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Acute kidney injury secondary to severe metabolic acidosis combined with hyperlacticaemia caused by amoxicillin: a case report]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> A case of severe metabolic acidosis combined with hyperlactatemia secondary acute kidney injury in a female patient after oral amoxicillin was analyzed to provide reference for clinical use. <b>Methods</b> The clinical characteristics, relevant examination and treatment plan of the patient were reviewed, and medication recommendations were put forward.<b>Results</b> One day after taking amoxicillin (2g) orally, the patient developed mental changes, progressive exacerbation, and disturbance of consciousness. Blood gas analysis suggested severe metabolic acidosis combined with hyperlactacemia. The correlation score of Naranjo’s adverse drug reactions of amoxicillin was 6 points (possibly related), the patient's severe metabolic acidosis and hyperlactacemia were "likely" caused by oral amoxicillin capsules, and acute kidney injury was secondary to severe acidosis. After treatment, the patient's condition quickly reversed and was discharged from hospital for 1 week.<b>Conclusion</b>  When unexplained changes occur in patients treated with amoxicillin, relevant tests should be performed immediately to rule out life-threatening adverse reactions such as severe metabolic acidosis and kidney failure. For amoxicillin related severe metabolic acidosis, it is necessary to fully evaluate and initiate continuous blood purification therapy if necessary to prevent further deterioration of the disease and improve the prognosis.]]></description>
<pubDate>2024/5/20 16:36:52</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[XU Baoping<sup>1</sup>, PENG Huaiwen<sup>1</sup>, YU Huaibin<sup>1</sup>, WANG Xiaotao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Baoping<sup>1</sup>, PENG Huaiwen<sup>1</sup>, YU Huaibin<sup>1</sup>, WANG Xiaotao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404017&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[One case of dystonia shock caused by rabeprazole sodium delayed-release capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To alert clinicians to adverse drug reactions of dystonia induced by rabeprazole sodium delayed-release capsules.<b>Methods</b>  The clinical data of one case of dystonia shock caused by rabeprazole sodium delayed-release capsules was analyzed while literature related to the  drug  adverse reactions.<b>Results</b>  Dystonia adverse drug reactions are rabeprazole sodium delayed-release capsules -induced new adverse drug reactions.<b>Conclusion</b>  Dystonia adverse reactions should be paid attention to in patients who first use rabeprazole sodium delayed-release capsule.]]></description>
<pubDate>2024/5/20 16:36:52</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[DONG Qiong, XU Wencheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DONG Qiong, XU Wencheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404018&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of tigecycline-induced serious adverse drug reactions in Shandong Province in past 10 years]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To analyze the characteristics of severe adverse reactions caused by tigecycline, and to provide reference for optimizing the treatment plan and reducing the incidence of adverse reactions.<b>Methods</b>  A retrospective analysis was performed on 99 cases of severe adverse reactions caused by tigecycline in Shandong Province from January 1,2013 to February 28,2023.<b>Results</b>  99 cases of serious adverse reactions, 75 cases of male, female 24 cases ;The mean age of the patients was ( 64±18 ) years. Hematological system damage ranked first, and the occurrence time ranged from 60 min to 25 d after administration. The results of adverse reactions showed that 13 cases were cured, 74 cases were improved, 3 cases were not improved, and 9 cases were unknown. The effect on the original disease was not obvious in 47 cases, resulting in 44 cases of prolonged course of disease and 8 cases of exacerbation. <b>Conclusion</b> It is suggested that pharmaceutical care should be carried out for middle-aged and elderly patients and high-risk patients prone to serious adverse reactions. Once serious adverse reactions occur, corresponding symptomatic treatment and supportive therapy should be carried out to ensure the safety of medication.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[WANG Ting<sup>1</sup>, CUI Xiaokang<sup>2</sup>, LI Min<sup>3</sup>, FENG Rui<sup>1</sup>, REN Jieru<sup>1</sup>, XU Xinping<sup>1</sup>, WU Jiyong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Ting<sup>1</sup>, CUI Xiaokang<sup>2</sup>, LI Min<sup>3</sup>, FENG Rui<sup>1</sup>, REN Jieru<sup>1</sup>, XU Xinping<sup>1</sup>, WU Jiyong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410019&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Signal mining and analysis of nervous system adverse events induced by polymyxin B and polymyxin E based on FAERS database]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide a reference basis for the rational clinical use of polymyxin B (PMB) and polymyxin E (PME). <b>Methods</b>  Based on the U. S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data from the first quarter of 2004 to the third quarter of 2024, data mining was conducted using Reporting Odds Ratios (ROR), Medicines and Healthcare products Regulatory Agency (MHRA) , and Bayesian Confidence Propagation Neural Network (BCPNN). <b>Results</b>  24 and 91 patients with nervous system adverse events (AE) related to PMB and PME, respectively. Most reports came from the US (70.83% for PMB, 30.77% for PME), with physicians and pharmacists as the main reporters. Most patients were relatively young (median age 32 for PMB and 48 for PME). In patients under 44 years of age, the constituent ratio of AE associated with PMB is higher than that with PME. PMB had a higher constituent ratio than PME in patients with cystic fibrosis and exacerbated lung disease (35.84% vs. 5.49%). PMB posed a greater constituent ratio of nervous system AE than PME (ROR [95% CI], 1.58 [1.13, 2.20]; PRR [95% CI], 1.51 [1.13, 2.01]; χ², 7.46; IC [IC-2SD], 0.59 [0.09]). PMB was associated with a higher constituent ratio of peripheral nervous system issues, while PME had a higher constituent ratio related to the neuromuscular tube. In addition, PMB and PME show different neurological AE at different drug doses. <b>Conclusion</b>  PMB and PME - related nervous system AE risks differ in age, indication, type, and drug dose. In clinical practice, attention should be paid to the use of neurotoxic protective agents, improve vigilance and other countermeasures to ensure the safety of patients.]]></description>
<pubDate>2025/9/17 10:50:07</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[GAO Hongzhu<sup>1</sup>, LIU Yue<sup>1</sup>, JIN Shanzi<sup>1</sup>, XU Fengping<sup>2</sup>, ZOU Dongna<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Hongzhu<sup>1</sup>, LIU Yue<sup>1</sup>, JIN Shanzi<sup>1</sup>, XU Fengping<sup>2</sup>, ZOU Dongna<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508016&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Data mining and analysis of adverse events signals for Montelukast Sodium in children based on FAERS database]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze post-marketing adverse event reported for Montelukast Sodium in children based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), and provide references for the safe clinical using of the drug. <b>Methods</b>  Disproportion analysis techniques, including the reporting odds ratio and proportional reporting ratio, were used to screen and analyze the signals of adverse events in children involving Montelukast Sodium from the FAERS database between the first quarter of 2004 and the first quarter of 2023. <b>Results</b>  A total of 12 148 case reports related to Montelukast Sodium were collected, of which 226 were found to be positive. These positive reactions were distributed in 18 different system and organ categories.According to the frequency of occurrence, the most frequent adverse signals of Montelukast Sodium are aggression, anxiety, abnormal behavior, depression, and suicidal thoughts, which can be seen in the drug label. In order of signal intensity, Montelukast induced visual deformations and the resulting Milfie syndrome were not mentioned in the drug label. <b>Conclusion</b>  Health care professionals should be extremely concerned about the possible neurological and psychiatric adverse events of Montelukast Sodium, especially when treating children and patients with related medical histories. And they should pay attention to adverse reactions not mentioned in the instructions.]]></description>
<pubDate>2025/4/7 9:36:37</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[LIAO Wen, HOU Wenjing, WEN Aiping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIAO Wen, HOU Wenjing, WEN Aiping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503016&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Investigation and analysis of the labeling of "athletes use with caution" of 428 Chinese patent medicine in hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the specific situation of "Athletes use with caution" in the instructions or outer packaging of Chinese patent medicine(CPM), to provide reference for the safe and rational use of CPM by athletes, and to provide suggestions for the management of CPM containing stimulants.<b>Methods</b>  All the instructions or outer packaging of CPM in use in a hospital were collected and sorted out, the CPM containing doping ingredients were screened according to the "2024 Doping Catalogue", and the differences compared by Comparative analysis method in the labeling of "Athletes use with caution".<b>Results</b>  A total of 428 kinds of traditional Chinese patent medicines and simple preparations were collected, including 86 kinds of traditional Chinese patent medicines and simple preparations containing stimulant ingredients. Only 44 kinds of instructions or packages were marked with "athletes use with caution", and the remaining 42 kinds were not marked. Most of the stimulant ingredients contained in the unmarked varieties were higenamine. No labelling but no stimulant content is involved.<b>Conclusion</b>  The labeling information or outer packaging of "Athletes use with caution" should be further improved to avoid iatrogenic misuse. At the same time, it is suggested that the drug regulatory department, together with the General Administration of Sports and other departments, strengthen the management of CPM containing stimulants and further regulate the clinical use of CPM containing stimulants.]]></description>
<pubDate>2026/1/6 16:37:08</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[REN Yiwen<sup>1</sup>, LIU Qun<sup>2</sup>, LIU Xiaoqian<sup>2</sup>, XIN Yizhou<sup>2</sup>, DAI Yanpeng<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>REN Yiwen<sup>1</sup>, LIU Qun<sup>2</sup>, LIU Xiaoqian<sup>2</sup>, XIN Yizhou<sup>2</sup>, DAI Yanpeng<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202512015&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of 426 cases of adverse reaction reports of Latamoxef for Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the adverse drug reaction( ADR )report data of latamoxef for injection, and to provide the basis for clinical rational drug use.<b>Methods</b>  Using the method of retrospective analysis and research, the ADR reports of latamoxef for injection collected in the database of Shandong Provincial Adverse Drug Reaction Monitoring Center from January 2019 to December 2023 were evaluated as positive, probable and possible by drug relevance evaluation. The age and gender of the patients in the ADR report caused by latamoxef for injection, the report of adverse reactions and the causality of ADR, the primary disease, usage and dosage, the distribution of ADR-involved organs and systems, the occurrence time of ADR,the new and serious adverse reactions and prognosis of ADR were statistically analyzed.<b>Results</b>  426 cases of ADR caused by latamoxef for injection were most distributed in children aged 0-10 years old, with a total of 219( 51.41% ) cases. The primary disease was mainly respiratory infection, with a total of 126 ( 29.58% )cases. The main route of administration of latamoxef for injection was intravenous drip, with a total of 417 ( 97.89% ) cases. The occurrence time of ADR was mainly within 1 h( 67.37% ). There were 12 organs and systems involved in ADR, with the most damage to skin and accessories, a total of 456 ( 71.59% ) cases. Among the 426 ADR reports, 271 patients were cured, 154 patients were improved, and 1 patient 's outcome was unknown.<b>Conclusion</b>  The clinical management of latamoxef for injection should be strengthened, strictly follow the instructions and strengthen the monitoring of patients, which can effectively reduce the occurrence of adverse reactions.]]></description>
<pubDate>2025/12/9 13:53:34</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[SUN Yushen<sup>1</sup>, LI Wei<sup>1</sup>, HAN Congxiao<sup>2</sup>, LIU Qun<sup>2</sup>, LIU Xiaoqian<sup>2</sup>, LU Changfei<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Yushen<sup>1</sup>, LI Wei<sup>1</sup>, HAN Congxiao<sup>2</sup>, LIU Qun<sup>2</sup>, LIU Xiaoqian<sup>2</sup>, LU Changfei<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202511015&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of adverse reactions and influencing factors of meropenem in the neonates]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Abstract</b>:<b>Objective</b>  To explore the safety of meropenem application in neonates, analyze the risk factors for adverse reactions, and provide references for the safe use of meropenem in clinical practice.<b>Methods</b>  The clinical data of meropenem related adverse reactions in newborns discharged from Liaocheng People's Hospital from January 2022 to March 2024 were analyzed by using the China Hospital Pharmacovigilance System. Logistic and other statistical methods were used to analyze the risk factors of adverse reactions.<b>Results</b>  367 cases were included in the study, and 63 positive cases were identified. The main adverse reactions were mental disorders and skin adnexal damage. Clinical outcome showed that 56 cases had relief or disappearance of symptoms. Multivariate analysis indicated that age ≤14 days, body weight ≥ 2.5 kg, duration ≥14 days were independent risk factors for adverse reactions (<i>P</i><0.05).<b>Conclusion</b>  Meropenem is relatively safe in neonates with mild adverse reaction symptoms. Identifying the risk factors of adverse reactions is helpful for clinical intervention and prevention, and improving the safety of using meropenem in neonates.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[YANG Xue<sup>1</sup>, ZHANG Fan<sup>1</sup>, SUN Qian<sup>1</sup>, WANG Meirong<sup>2</sup>, ZHAO Ping<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Xue<sup>1</sup>, ZHANG Fan<sup>1</sup>, SUN Qian<sup>1</sup>, WANG Meirong<sup>2</sup>, ZHAO Ping<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603017&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[吉西他滨单药与联用卡培他滨方案在胰腺癌患者中的不良事件信号挖掘：一项基于FAERS数据库的对比性分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:26</pubDate>
<category><![CDATA[Adverse Drug Reactions]]></category>
<author><![CDATA[李一彬<sup>1</sup>，武扬<sup>2</sup>，刘星<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李一彬<sup>1</sup>，武扬<sup>2</sup>，刘星<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610016&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>